These new therapeutic opportunities, associated with emerging immunotherapy, i.e., monoclonal antibodies (anti-CD33 in immature T-ALL or anti-CD30 in antigen-expressing cases), or CART-T or NK cell approaches directed against CD4, CD3, CD1a, CD5 T-cell antigens, will hopefully change the outlook of this aggressive subtype of leukemias. Here, CD33 is linked to acute lymphoblastic leukemia.